Gliknik Announces Issuance of U.S. Patent for Use of Recombinant IVIG Mimetics

Patent covers uses of recombinant compounds with at least two human IgG1 Fc domains that bind receptors found on immune cells BALTIMORE, April 3, 2018 /PRNewswire/ -- Gliknik Inc. today announced that the U.S. Patent & Trademark Office (PTO) has issued U.S. Patent 9,926,362, which claims methods of using compounds that have utility as recombinant...

Patent covers uses of recombinant compounds with at least two human IgG1 Fc domains that bind receptors found on immune cells

BALTIMORE, April 3, 2018 /PRNewswire/ -- Gliknik Inc. today announced that the U.S. Patent & Trademark Office (PTO) has issued U.S. Patent 9,926,362, which claims methods of using compounds that have utility as recombinant mimetics of pooled human intravenous immunoglobulin (IVIG). The patent, which issued jointly to Gliknik Inc. and to the University of Maryland, Baltimore (UMB), encompasses the uses of trimers, tetramers, pentamers, hexamers, and many other structures containing two or more human IgG1 Fc domains and binding multiple low affinity Fc gamma receptors (FcγRs).

"We are pleased to have the U.S. PTO recognize the novelty of methods we describe for using a range of recombinant compounds to bind multiple low affinity FcγRs on effector cells," said Henrik Olsen, PhD, Gliknik Vice President of Drug Discovery. "We believe that such compounds will progress through clinical trials successfully and may expand the marketplace choices for patients with autoimmune diseases."

James L. Hughes, Chief Enterprise and Economic Development Officer and Vice President at UMB, added, "We are proud of this patent issuance and look forward to the potential for a marketed recombinant IVIG product that will increase options for patients. We congratulate Gliknik for successfully leading the prosecution of this patent application on behalf of Gliknik and UMB."

Click here to read the rest of the story via PR Newswire.

Source: www.umbiopark.com